Athena Athena

X

Find Drugs in Development News & Deals for Raloxifene Hydrochloride

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

JDMFs Filed

JDMFs Filed

Other Certificates

Other Certificates

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)
836
INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

JP

0

Other Listed Suppliers

SERVICES

Details:

Two papers, published in The Lancet and Nature, indicate that treatment with oral raloxifene, a selective estrogen receptor modulator (SERM) with a proven safety profile, may be efficacious against SARS-CoV-2 clinically relevant variants.


Lead Product(s): Raloxifene Hydrochloride

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 26, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

AD101 (Raloxifene), a 100 Series lead compound and a novel T-type calcium channel modulator demonstrated statistically significant improvement in both core symptoms of AD in Concept Trials.


Lead Product(s): Raloxifene Hydrochloride

Therapeutic Area: Neurology Product Name: AD101

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Societal CDMO

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 01, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under terms of the new contract, Societal will execute a range of clinical trial services to support the initiation of Phase 3 and Phase 4 clinical studies of AD101 (raloxifene).


Lead Product(s): Raloxifene Hydrochloride

Therapeutic Area: Neurology Product Name: AD101

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: AmyriAD

Deal Size: $1.0 million Upfront Cash: Undisclosed

Deal Type: Agreement June 01, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
  • Deals

Details:

This agreement covers the exchange of clinical and nonclinical trial information related to COVID-19 treatment using the repurposed Raloxifene molecule developed by five research organisations from the EU and South Korea.


Lead Product(s): Raloxifene Hydrochloride

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: UndisclosedProduct Type: Small molecule

Partner/Sponsor/Collaborator: CINECA

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement November 18, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

A patent on the use of raloxifene for the treatment of people affected by COVID-19 was filed by Dompé farmaceutici, Fraunhofer Institute and Leuven University to promote universal access to related therapies that may be developed, in line with Exscalate4Cov’s guidelines.


Lead Product(s): Raloxifene Hydrochloride

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: UndisclosedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 27, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY